INGN
Inogen Inc

1,454
Mkt Cap
$186.78M
Volume
147,637.00
52W High
$12.91
52W Low
$5.70
PE Ratio
-6.87
INGN Fundamentals
Price
$6.90
Prev Close
$6.88
Open
$6.81
50D MA
$8.23
Beta
1.35
Avg. Volume
150,585.74
EPS (Annual)
-$1.52
P/B
0.95
Rev/Employee
$438,257.18
Loading...
Loading...
News
all
press releases
Down 19.2% in 4 Weeks, Here's Why You Should You Buy the Dip in Inogen (INGN)
Inogen (INGN) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.
Zacks·17h ago
News Placeholder
More News
News Placeholder
Inogen Stock Dips Despite Q3 Earnings Beat, Revenues Up Y/Y
INGN stock slid despite a narrower Q3 loss and rising B2B demand, as weaker consumer and rental sales weighed on results.
Zacks·9d ago
News Placeholder
Inogen (INGN) Reports Q3 Loss, Misses Revenue Estimates
Inogen (INGN) delivered earnings and revenue surprises of +9.09% and -0.12%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·10d ago
News Placeholder
Inogen Announces Third Quarter 2025 Financial Results
Inogen, Inc. (Nasdaq: INGN), a medical technology company offering innovative respiratory products for use in the homecare setting, today announced financial results for the quarter ended September...
Business Wire·10d ago
News Placeholder
Inogen to Report Third Quarter 2025 Financial Results on November 5, 2025
Inogen, Inc. (Nasdaq: INGN), a medical technology company offering innovative respiratory products for use in the homecare setting, today announced that it will report third quarter 2025 financial...
Business Wire·1mo ago
News Placeholder
Why Fast-paced Mover Inogen (INGN) Is a Great Choice for Value Investors
Inogen (INGN) could be a great choice for investors looking to buy stocks that have gained strong momentum recently but are still trading at reasonable prices. It is one of the several stocks that made it through our 'Fast-Paced Momentum at a Bargain' screen.
Zacks·2mo ago
News Placeholder
GEHC Inks License Agreement With Lantheus for Prostate Imaging Agent
GE HealthCare strengthens its radiopharmaceutical portfolio by licensing Lantheus' PSMA PET imaging agent, PYLARIFY, for commercialization in Japan.
Zacks·2mo ago
News Placeholder
Masimo Completes Divestment of Consumer Audio Business to HARMAN
MASI completes sale of Sound United to HARMAN, sharpening focus on core healthcare, boosting margins, and funding buybacks.
Zacks·2mo ago
News Placeholder
Here's Why You Should Add Inogen Stock to Your Portfolio Now
Expanding product portfolio and high prospects for POC raise optimism for INGN stock.
Zacks·2mo ago
News Placeholder
Reasons to Add West Pharmaceutical Stock to Your Portfolio Now
WST rides on GLP-1 demand and Annex 1 expansion, but margins face pressure from pricing and tariff headwinds.
Zacks·2mo ago

Latest INGN News

View

Advertisement|Remove ads.

Advertisement|Remove ads.